Molecular Heterogeneity, Biomarker Discovery, and Targeted Therapy in Asthma - Genomic Biomarkers for Pharmaceutical Development - page 89

[14] Martin RJ, Szeler SJ, King TS, Kraft M, Boushey HA, Chinchilli VM, et al. The predicting response to inhaled
corticosteroid eficacy (PRICE) trial. J Allergy Clin Immunol 2007;119:73-80.
[15] Hauber HP, Gotfried M, Newman K, Danda R, Servi RJ, Christodoulopoulos P, et al. Effect of HFA-lunisolide
on peripheral lung inlammation in asthma. J Allergy Clin Immunol 2003;112:58-63.
[16] Kharitonov SA, Donnelly LE, Montuschi P, Corradi M, Collins JV, Barnes PJ. Dose-dependent onset and
cessation of action of inhaled budesonide on exhaled nitric oxide and symptoms in mild asthma. Thorax
2002;57:889-96.
[17] McNicholl DM, Stevenson M, McGarvey LP, Heaney LG. The utility of fractional exhaled nitric oxide suppres-
sion in the identiication of nonadherence in dificult asthma. Am J Respir Crit Care Med 2012;186:1102-8.
[18] Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, et al. Asthma exacerbations and
sputum eosinophil counts: a randomised controlled trial. Lancet 2002;360:1715-21.
[19] Jayaram L, Pizzichini MM, Cook RJ, Boulet LP, Lemiere C, Pizzichini E, et al. Determining asthma treatment
by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006;27:483-94.
[20] Powell H, Murphy VE, Taylor DR, Hensley MJ, McCaffery K, Giles W, et al. Management of asthma in preg-
nancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial.
Lancet 2011;378:983-90.
[21] Braman SS. The global burden of asthma. Chest 2006;130:4S-12S.
[22] Blakey JD, Wardlaw AJ. What is severe asthma? Clin Exp Allergy 2012;42:617-24.
[23] Heaney LG, Horne R. Non-adherence in dificult asthma: time to take it seriously. Thorax 2012;67:268-70.
[24] Adcock IM, Barnes PJ. Molecular mechanisms of corticosteroid resistance. Chest 2008;134:394-401.
[25] Tantisira KG, Lasky-Su J, Harada M, Murphy A, Litonjua AA, Himes BE, et al. Genomewide association
between GLCCI1 and response to glucocorticoid therapy in asthma. N Engl J Med 2011;365:1173-83.
[26] Catley MC, Coote J, Bari M, Tomlinson KL. Monoclonal antibodies for the treatment of asthma. Pharmacol
Ther 2011;132:333-51.
[27] Holgate ST. Trials and tribulations in identifying new biologic treatments for asthma. Trends Immunol
2012;33:238-46.
[28] Pelaia G, Vatrella A, Maselli R. The potential of biologics for the treatment of asthma. Nat Rev Drug Discov
2012;11:958-72.
[29] Holgate ST. Stratified approaches to the treatment of asthma. Br J Clin Pharmacol 2012. doi: http://dx.doi.
org/10.1111/bcp.12036 .
[30] Wenzel S. Severe asthma: from characteristics to phenotypes to endotypes. Clin Exp Allergy 2012;42:650-8.
[31] Woodruff PG, Boushey HA, Dolganov GM, Barker CS, Yang YH, Donnelly S, et al. Genome-wide proiling
identiies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc
Natl Acad Sci USA 2007;104:15858-15863.
[32] Holgate ST. Pathophysiology of asthma: what has our current understanding taught us about new therapeutic
approaches? J Allergy Clin Immunol 2011;128:495-505.
[33] Winpenny JP, Marsey LL, Sexton DW. The CLCA gene family: putative therapeutic target for respiratory dis-
eases. Inlamm Allergy Drug Targets 2009;8:146-60.
[34] Patel AC, Brett TJ, Holtzman MJ. The role of CLCA proteins in inlammatory airway disease. Annu Rev
Physiol 2009;71:425-49.
[35] Alevy YG, Patel AC, Romero AG, Patel DA, Tucker J, Roswit WT, et al. IL-13-induced airway mucus produc-
tion is attenuated by MAPK13 inhibition. J Clin Invest 2012;122:4555-68.
[36] Schroder WA, Gardner J, Le TT, Duke M, Burke ML, Jones MK, et al. SerpinB2 deiciency modulates Th1/Th2
responses after schistosome infection. Parasite Immunol 2010;32:764-8.
[37] Schroder WA, Le TT, Major L, Street S, Gardner J, Lambley E, et al. A physiological function of inlammation-
associated SerpinB2 is regulation of adaptive immunity. J Immunol 2010;184:2663-70.
[38] Norris RA, Moreno-Rodriguez R, Hoffman S, Markwald RR. The many facets of the matricelluar protein
periostin during cardiac development, remodeling, and pathophysiology. J Cell Commun Signal 2009;3:
275-86.
[39] Takayama G, Arima K, Kanaji T, Toda S, Tanaka H, Shoji S, et al. Periostin: a novel component of subepithelial
ibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol 2006;118:98-104.
[40] Sidhu SS, Yuan S, Innes AL, Kerr S, Woodruff PG, Hou L, et al. Roles of epithelial cell-derived periostin in
TGF-β activation, collagen production, and collagen gel elasticity in asthma. Proc Natl Acad Sci USA
2010;107(32):14170-5.